Back to discover
Drug
BMS-275183
Early clinical developmentClassTubulin stabiliser
15
Protein targets
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this drug.
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
Clinical trial2010-03-02Terminated · ClinicalTrials.gov
Clinical trial2010-03-02Terminated · ClinicalTrials.gov
Clinical trial2010-03-02Terminated · ClinicalTrials.gov
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Canonical name
BMS-275183
RxNorm CUI
320847
ChEMBL ID
CHEMBL4297268
UNII
UQC681JJIV
Primary mechanism
Tubulin stabiliser
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY3
registered trials across all phases
3
Discontinued
PHASE DISTRIBUTIONn = 3
Phase 11Phase 22
References & data sources
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials